PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 4,033 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $76.56, for a total value of $308,766.48. Following the completion of the transaction, the vice president owned 113,626 shares in the company, valued at $8,699,206.56. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.93, for a total value of $180,330.02.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total value of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total value of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.99, for a total transaction of $213,683.88.

PTC Therapeutics Stock Up 0.1%

Shares of PTCT stock traded up $0.06 during trading hours on Monday, reaching $77.59. 2,631,928 shares of the stock traded hands, compared to its average volume of 1,795,906. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The business has a fifty day moving average price of $76.61 and a 200 day moving average price of $62.91. The firm has a market capitalization of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same quarter last year, the business posted ($1.39) EPS. The company’s revenue was up 7.2% on a year-over-year basis. Research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PTCT. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. TD Cowen upped their target price on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Royal Bank Of Canada downgraded shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their price objective for the company from $82.00 to $91.00 in a research report on Monday, December 1st. Finally, Citigroup upped their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $77.27.

Institutional Trading of PTC Therapeutics

Several large investors have recently added to or reduced their stakes in PTCT. Empowered Funds LLC bought a new position in shares of PTC Therapeutics during the 1st quarter valued at $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after buying an additional 18,504 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of PTC Therapeutics by 62.8% in the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock worth $2,003,000 after buying an additional 15,167 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of PTC Therapeutics by 6.1% during the 1st quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock worth $1,904,000 after acquiring an additional 2,140 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of PTC Therapeutics during the 1st quarter valued at about $438,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.